Johnson & Johnson (NYSE:JNJ) is reportedly considering selling its stroke care unit, Cerenovus, in a deal that could value the business at more than $1 billion. The move aligns with the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback